Stocks › GNPX

Genprex, Inc.

GNPX·Nasdaq·United States United States·USD
$1.45
-0.22 (-13.17%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
GNPX
Genprex, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
GNPXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of GNPX by members of U.S. Congress · 4 on record · 3 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Tim MooreTim MooreHouse · R · NC GNPXGenprex, Inc. · Stock Purchase
$1,001 - $15,000
Feb 20, 2026 Feb 5, 2026 Filing ↗
Tim MooreTim MooreHouse · R · NC GNPXGenprex, Inc. · Stock Purchase
$1,001 - $15,000
Jan 7, 2026 Dec 18, 2025 Filing ↗
Tim MooreTim MooreHouse · R · NC GNPXGenprex, Inc. · Stock Purchase
$1,001 - $15,000
Dec 2, 2025 Nov 7, 2025 Filing ↗
Tim MooreTim MooreHouse · R · NC GNPXGenprex, Inc. · Stock Purchase
$15,001 - $50,000
Nov 12, 2025 Oct 29, 2025 Filing ↗

Whale Activity

Position changes in GNPX reported for 2026-09-30 by 26 institutional filers
New: 1Decreased: 2Closed: 8No prior filing: 15
  • Increased0
  • New1
  • Held0
  • Decreased2
  • Closed8
  • No prior filing15

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by GNPX insiders, by quarter · Form 4
-20-10010202025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: -182026 Q22026 Q3: 02026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

44 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
LONGNECKER BRENT MDirector Sale −10 $1.23 $12 Apr 14, 2026 Form 4 ↗
LONGNECKER BRENT MDirector Sale −8 $1.23 $10 Apr 14, 2026 Form 4 ↗
Berger Mark StanleyChief Medical Officer Tax withholding −7,168 $2.00 $14K Feb 27, 2026 Form 4 ↗
Confer Ryan M.President, CEO and CFO · Director Tax withholding −9,330 $2.00 $19K Feb 27, 2026 Form 4 ↗
Moreno Toscano Jose AntonioDirector Grant / award +9,000 $0.00 $0 Dec 22, 2025 Form 4 ↗
Berger Mark StanleyChief Medical Officer Grant / award +28.5K $0.00 $0 Dec 22, 2025 Form 4 ↗
Confer Ryan M.President, CEO and CFO · Director Grant / award +45.0K $0.00 $0 Dec 22, 2025 Form 4 ↗
LONGNECKER BRENT MDirector Grant / award +9,000 $0.00 $0 Dec 22, 2025 Form 4 ↗
Wilson William R Jr.Director Grant / award +9,000 $0.00 $0 Dec 22, 2025 Form 4 ↗
Berger Mark StanleyChief Medical Officer Tax withholding −4,500 $0.23 $1K Jun 30, 2025 Form 4 ↗
Confer Ryan M.President, CEO and CFO · Director Tax withholding −5,775 $0.23 $1K Jun 30, 2025 Form 4 ↗
Berger Mark StanleyChief Medical Officer Tax withholding −585 $0.41 $240 Feb 18, 2025 Form 4 ↗
Confer Ryan M.President, CEO and CFO · Director Tax withholding −395 $0.41 $162 Feb 18, 2025 Form 4 ↗
Moreno Toscano Jose AntonioDirector Grant / award +4,750 $0.00 $0 Dec 5, 2024 Form 4 ↗
Wilson William R Jr.Director Grant / award +4,750 $0.00 $0 Dec 5, 2024 Form 4 ↗
LONGNECKER BRENT MDirector Grant / award +4,750 $0.00 $0 Dec 5, 2024 Form 4 ↗
Confer Ryan M.President, CEO and CFO · Director Grant / award +29.4K $0.00 $0 Dec 5, 2024 Form 4 ↗
Berger Mark StanleyChief Medical Officer Grant / award +18.3K $0.00 $0 Dec 5, 2024 Form 4 ↗
Berger Mark StanleyChief Medical Officer Tax withholding −1,319 $4.40 $6K Feb 18, 2024 Form 4 ↗
Varner John RodneyChairman, President and CEO · Director Tax withholding −2,642 $4.40 $12K Feb 18, 2024 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding GNPX · SEC Form N-PORT
FundSharesValue% of fundAs of
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
9,122$34K0.00%Aug 31, 2026
Fidelity Series Total Market Index Fund
Fidelity Concord Street Trust
70$2600.00%Aug 31, 2026
Fidelity Total Market Index Fund
Fidelity Concord Street Trust
32$1190.00%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list GNPX's shares (CUSIP 372446401), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Waqas KhatriSCHEDULE 13G/A · passive (13G) · 249.8K shares2.7%
    May 11, 2026 · ↗
  • Alto Opportunity Master Fund, SPC - Segregated Master Portfolio BSCHEDULE 13G/A · passive (13G) · 249.8K shares2.7%
    May 11, 2026 · ↗
  • Ayrton Capital LLCSCHEDULE 13G/A · passive (13G) · 249.8K shares2.7%
    May 11, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Genprex, Inc. as client

No lobbying filings found naming Genprex, Inc. as the client.

Government Contracts

Federal awards to Genprex, Inc. · USAspending

No federal contract awards found for Genprex, Inc..

U.S. Patents

Recent USPTO applications naming Genprex, Inc.

No USPTO patent applications found for Genprex, Inc..

Annual Financials

From GNPX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenuen/a$0$0$0$0
Operating income-$15.5M-$21.2M-$31.1M-$23.8M-$20.7M
Net income-$16.2M-$21.1M-$30.9M-$23.7M-$20.7M
Operating cash flow-$15.3M-$17.9M-$24.7M-$17.6M-$14.3M
Cash and equivalents$7.8M$1.6M$6.7M$21.0Mn/a
Total assets$10.2M$4.1M$10.7M$25.1M$42.9M
Total liabilities$2.2M$2.5Mn/an/a$1.6M
Shareholders' equity$8.0M$1.6M$7.4M$22.3M$41.3M

As Genprex, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 30, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-22Reverse splitJul 16, 2026
  • 1-for-50Reverse splitOct 21, 2025
  • 1-for-40Reverse splitFeb 2, 2024

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 8.01, 9.01Other eventsNov 5, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsOct 28, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsOct 21, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 18, 2026
    EDGAR ↗
  • 8-K · Items 3.01, 9.01Delisting noticeAug 5, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 3, 2026
    EDGAR ↗
  • 8-K · Items 3.01, 8.01, 9.01Delisting notice · Other eventsJul 30, 2026
    EDGAR ↗
  • 8-K · Items 3.03, 5.03, 7.01, 8.01, 9.01Modification of rights · Bylaw amendment · Reg FD disclosureJul 14, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 22, 2026
    EDGAR ↗

About Genprex, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersAUSTIN, TX
IncorporatedTX